Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy

Last updated: October 22, 2023
Sponsor: Sun Yat-sen University
Overall Status: Completed

Phase

2

Condition

Nasopharyngeal Cancer

Carcinoma

Treatment

Anlotinib

Clinical Study ID

NCT03906058
B2018-167
  • Ages 18-70
  • All Genders

Study Summary

The purpose of this single arm, phase Ⅱ clinical trial is to evaluate the efficacy and safety of Anlotinib Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma after failure of no less than second-line chemotherapy or targeted therapy

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • biopsy proved nasopharyngeal carcinoma;
  • stage IVB according to American Joint Committee on Cancer(AJCC) edition VIII, orrecurrent disease after chemotherapy and/or radiotherapy;
  • 18 years or older; without other malignancy;
  • proper functioning of the major organs.

Exclusion

Exclusion Criteria:

  • allergic to anlotinib;
  • female within gestation period or lactation;
  • patients received drug of other clinical trial within 4 weeks.

Study Design

Total Participants: 39
Treatment Group(s): 1
Primary Treatment: Anlotinib
Phase: 2
Study Start date:
April 29, 2019
Estimated Completion Date:
April 30, 2022

Connect with a study center

  • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

    Guangzhou, Guangdong 510000
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.